Publicaciones en las que colabora con JESÚS FERNANDO SAN MIGUEL IZQUIERDO (47)

2013

  1. Analysis of incidence, risk factors and clinical outcome of thromboembolic and bleeding events in 431 allogeneic hematopoietic stem cell transplantation recipients

    Haematologica, Vol. 98, Núm. 3, pp. 437-443

2011

  1. Effect of vitamin D treatment in chronic GVHD

    Bone Marrow Transplantation

2010

  1. Liver function tests and absolute lymphocyte count at day +100 are predictive factors for extensive and severe chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplant

    American Journal of Hematology, Vol. 85, Núm. 4, pp. 290-293

  2. The combination of thalidomide, cyclophosphamide and dexamethasone is potentially useful in highly resistant Hodgkin's lymphoma

    European Journal of Haematology, Vol. 84, Núm. 3, pp. 266-270

2009

  1. Oral Beclomethasone Dipropionate for the Treatment of Gastrointestinal Chronic Graft-versus-Host Disease

    Biology of Blood and Marrow Transplantation, Vol. 15, Núm. 10, pp. 1331-1336

2008

  1. Prognostic Factors of Chronic Graft-versus-Host Disease Following Allogeneic Peripheral Blood Stem Cell Transplantation: The National Institutes Health Scale Plus the Type of Onset Can Predict Survival Rates and the Duration of Immunosuppressive Therapy

    Biology of Blood and Marrow Transplantation, Vol. 14, Núm. 10, pp. 1163-1171

2006

  1. Oral Beclomethasone Dipropionate for the Treatment of Gastrointestinal Acute Graft-versus-Host Disease (GVHD)

    Biology of Blood and Marrow Transplantation, Vol. 12, Núm. 9, pp. 936-941

  2. Reduced-intensity conditioning allogeneic transplantation is associated with a high incidence of extramedullary relapses in multiple myeloma patients [14]

    Leukemia

  3. Vincristine is an effective therapeutic approach for transplantation-associated thrombotic microangiopathy [5]

    Bone Marrow Transplantation

2005

  1. CD34+ cell dose and outcome of patients undergoing reduced-intensity-conditioning allogeneic peripheral blood stem cell transplantation

    Leukemia and Lymphoma, Vol. 46, Núm. 2, pp. 177-183

  2. Effect of pre-transplant cumulative doses of chemotherapeutic drugs on early and long-term hematological recovery after autologous bone-marrow transplantation for lymphoma

    Haematologica, Vol. 90, Núm. 1, pp. 78-85

  3. Gene expression profile reveals deregulation of genes with relevant functions in the different subclasses of acute myeloid leukemia

    Leukemia, Vol. 19, Núm. 3, pp. 402-409

  4. Long-term immune recovery of patients undergoing allogeneic stem cell transplantation: A comparison with their respective sibling donors

    Biology of Blood and Marrow Transplantation, Vol. 11, Núm. 5, pp. 354-361

  5. Posttransplant hematopoiesis in patients undergoing sibling allogeneic stem cell transplantation reflects that of their respective donors although with a lower functional capability

    Experimental Hematology, Vol. 33, Núm. 8, pp. 935-943

  6. Reduced-intensity conditioning allogeneic blood stem cell transplantation with fludarabine and oral busulfan with or without pharmacokinetically targeted busulfan dosing in patients with myeloid leukemia ineligible for conventional conditioning

    Biology of Blood and Marrow Transplantation, Vol. 11, Núm. 6, pp. 437-447

  7. Successful treatment of rhinocerebral zygomycosis with a combination of caspofungin and liposomal amphotericin B.

    Haematologica, Vol. 90, Núm. 12 Suppl

2004

  1. Antibiotic prophylaxis with meropenem after allogeneic stem cell transplantation

    Bone Marrow Transplantation, Vol. 33, Núm. 2, pp. 183-187

  2. Effect of cumulative etoposide doses on the outcome of autologous peripheral-blood progenitor-cell transplantation for lymphoma

    Bone Marrow Transplantation, Vol. 33, Núm. 6, pp. 579-587

2003

  1. Immunophenotypic analysis of peripheral blood stem cell harvests from patients with multiple myeloma

    Haematologica, Vol. 88, Núm. 9, pp. 1013-1021

  2. Impact of CD34+ cell dose on the outcome of patients undergoing reduced-intensity-conditioning allogeneic peripheral blood stem cell transplantation

    Blood, Vol. 102, Núm. 3, pp. 1108-1113